accur
rapid
diagnost
test
facilit
better
patient
care
inform
prompt
appropri
treatment
lead
decreas
morbid
mortal
save
money
prevent
improp
use
antimicrobi
drug
rapid
diagnost
also
critic
identifi
pathogen
target
public
health
intervent
employ
control
diseas
transmiss
commun
nucleic
acid
amplif
technolog
naat
identifi
common
pathogen
becom
routin
approach
infecti
diseas
diagnosi
highincom
countri
mani
naat
product
exist
clear
approv
nation
health
author
agenc
addit
varieti
qualifi
laboratorydevelop
method
use
facil
although
variou
amplif
methodolog
develop
rtpcr
predomin
naat
use
diagnost
test
implement
naat
clinic
diagnost
laboratori
complex
requir
sophist
equip
infrastructur
skill
laboratorian
robust
qualiti
manag
program
requir
present
insurmount
challeng
tri
diagnos
infecti
diseas
resourc
limit
set
rl
low
middleincom
countri
lmic
especi
rural
environ
oper
logist
limit
challeng
implement
patient
communic
diseas
locat
would
greatli
benefit
rapid
onsit
diagnosi
time
linkag
care
result
improv
individu
outcom
better
infecti
diseas
control
multifacet
challeng
face
naat
pointofcar
test
lmic
demand
solut
reliabl
integr
often
challeng
nucleic
acid
na
extract
procedur
togeth
suitabl
na
amplificationdetect
method
unifi
system
must
simpl
oper
environment
robust
yield
time
result
afford
high
diagnost
accuraci
naatbas
diagnost
platform
develop
use
highincom
countri
typic
toler
environment
extrem
eg
temperatur
humid
dust
encount
rl
design
use
healthcar
worker
receiv
extens
train
factor
make
current
avail
sampletoansw
naat
option
unsuit
implement
peripher
facil
lmic
rapid
time
result
necessari
reduc
loss
follow
wherein
client
may
multipl
constraint
prevent
return
test
result
possibl
treatment
includ
distanc
requir
travel
test
site
timeoff
work
visit
limit
financi
resourc
compet
need
current
naat
test
result
infecti
diseas
avail
day
cost
per
test
barrier
adopt
mani
lmic
purchas
highcost
diagnost
test
without
global
donor
support
exampl
publish
target
product
profil
simpl
accur
diagnost
naat
mycobacterium
tuberculosi
mtb
supplant
smear
microscopi
target
price
us
set
global
need
innov
design
develop
low
cost
fulli
integr
test
system
meet
requir
perform
criteria
function
auster
environ
applic
varieti
pathogen
agent
high
qualiti
na
extract
necessari
first
step
toward
integr
platform
assess
perform
six
na
extract
technolog
effici
extract
high
qualiti
na
complex
clinic
sampl
matric
sputum
stool
whole
blood
varieti
metric
use
evalu
assess
perform
six
platform
intent
determin
might
subsequ
integr
togeth
lowcost
na
detect
technolog
also
suitabl
rl
blind
panel
qualiti
control
contriv
specimen
sputum
blood
stool
spike
vari
level
bacteri
andor
viral
agent
use
headtohead
challeng
six
na
extract
technolog
perform
compar
use
pathogenspecif
realtim
pcr
assay
target
factor
import
rl
assess
includ
specimen
input
volum
larg
sensit
degre
autom
process
time
collect
data
compil
analyz
gaug
suitabl
six
technolog
futur
inclus
lmicappropri
integr
test
subject
ongo
interest
funder
bill
melinda
gate
foundat
bmgf
extens
search
peerreview
literatur
publish
technic
report
white
paper
commerci
literatur
compani
websit
confer
proceed
letter
interest
donor
bmgf
conduct
identifi
multipl
technolog
develop
innov
na
extract
method
potenti
use
auster
set
six
develop
agre
particip
studi
base
upon
estim
potenti
meet
critic
cost
goal
approxim
per
extract
institut
includ
akonni
biosystem
inc
frederick
md
usa
claremont
biosolut
upland
ca
usa
integr
nanotechnolog
henrietta
ny
usa
molbio
diagnost
bangalor
india
paratu
diagnost
san
marco
tx
usa
hasleton
group
vanderbilt
univers
nashvil
tn
usa
although
institut
role
design
studi
author
agre
request
purpos
anonym
ident
develop
associ
technolog
would
code
report
develop
offer
sever
innov
devic
na
extract
method
incorpor
variou
chemic
heat
andor
mechan
lysi
solid
phase
na
captur
silica
naspecif
bind
matric
coat
onto
bead
frit
support
oper
platform
rang
prototyp
system
develop
simplifi
workflow
fulli
integr
devic
develop
receiv
ident
blind
specimen
panel
process
facil
isol
na
ship
center
diseas
control
prevent
cdc
subsequ
molecular
analysi
multipl
studi
perform
na
platform
describ
previous
thu
work
util
real
time
pcr
analys
sampl
extract
establish
suffici
amount
puriti
target
na
gener
give
posit
result
human
raw
sputum
whole
blood
stool
specimen
matric
use
studi
common
specimen
type
use
diagnosi
mani
infecti
diseas
consid
complex
physiochem
attribut
includ
viscos
heterogen
extran
na
commens
microflora
cellular
debri
presenc
pcr
inhibitor
intent
studi
directli
compar
differ
na
extract
method
use
contriv
sampl
deliber
chosen
limit
heterogen
sampl
type
compar
clinic
deriv
sampl
addit
acquisit
suffici
amount
excess
discard
clinic
sampl
use
multipl
method
would
extrem
challeng
group
describ
use
contriv
sampl
order
compar
perform
differ
extract
method
test
platform
diagnost
laboratori
host
test
platform
aliquot
pool
raw
human
sputum
x
ml
volum
stool
x
g
procur
bioivt
westburi
ny
usa
bloodwork
northwest
seattl
wa
usa
provid
one
unit
ml
human
whole
blood
total
na
first
extract
specimen
screen
via
realtim
rtpcr
path
use
protocol
describ
confirm
absenc
target
microb
includ
primari
specimen
king
counti
tuberculosi
laboratori
seattl
wa
usa
screen
aliquot
pool
sputum
sampl
presenc
absenc
mtb
via
mycobacteri
growth
indic
tube
mgit
becton
dickinson
franklin
lake
nj
usa
middlebrook
agar
slant
specimen
type
stool
sputum
whole
blood
spike
bacteria
andor
rnabas
viru
enabl
semiquantit
pcr
assess
dna
rna
extract
effici
specimen
panel
real
time
pcr
assay
use
studi
qualit
quantit
assess
extract
perform
specimen
matric
spike
target
microb
level
repres
high
medium
low
level
target
assum
method
assess
exercis
would
detect
high
level
like
medium
rang
detect
low
level
extract
primari
indic
perform
term
recoveri
puriti
extract
mtb
strain
johannesburg
clinic
isol
influenza
use
sputum
spike
salmonella
enterica
serovar
typhimurium
male
specif
bacteriophag
use
stool
streptococcu
pneumonia
phage
use
whole
blood
inactiv
mtb
cell
procur
laboratori
dr
bavesh
kana
univers
witwatersrand
johannesburg
south
africa
suppli
ten
ml
phosphat
buffer
salin
pb
mtb
cell
origin
cultur
middlebrook
broth
supplement
glycerol
incub
mtb
cell
chemic
inactiv
ensur
minim
risk
laboratoryacquir
infect
process
growth
mgit
day
incub
confirm
inactiv
mtb
influenza
strain
clinic
isol
provid
washington
state
depart
health
public
health
laboratori
shorelin
wa
usa
dr
scott
meschk
univers
washington
seattl
wa
usa
gift
phage
typhimurium
phage
propag
escherichia
coli
famp
strain
previous
describ
harvest
soft
agar
overlay
filter
filter
emd
millipor
billerica
usa
stock
store
use
typhimurium
cultur
tryptic
soy
broth
sigmaaldrich
st
loui
mi
usa
overnight
incub
shake
cell
pellet
centrifug
wash
pb
resuspend
ml
pb
store
use
pneumonia
american
type
cultur
collect
manassa
va
usa
cultur
overnight
brainheart
infus
broth
sigmaaldrich
cell
pellet
centrifug
wash
pb
resuspend
glycerol
sigmaaldrich
prevent
autolysi
cell
suspens
aliquot
stock
volum
store
use
except
mtb
extract
bacteri
viral
na
path
laboratori
perform
use
qiagen
na
extract
kit
hilden
germani
describ
na
eluat
deriv
extract
store
use
viral
rna
spike
sputum
blood
panel
member
extract
use
aliquot
specimen
process
qiaamp
viral
rna
mini
kit
follow
manufactur
protocol
rna
elut
final
volum
viral
rna
spike
stool
panel
member
prerna
extract
cleanup
step
done
follow
briefli
mg
amount
stool
homogen
pb
via
vortex
clarifi
centrifug
minut
x
g
supernat
filter
use
filter
emd
millipor
aliquot
filtrat
process
qiaamp
viral
rna
mini
kit
bacteri
dna
blood
extract
use
process
qiaamp
dna
blood
mini
kit
elut
final
volum
bacteri
dna
stool
extract
mg
use
qiaamp
dna
stool
mini
kit
elut
volum
mtb
dna
extract
sputum
use
previou
methodolog
briefli
sampl
volum
liquefi
use
equal
volum
nacetyllcystein
incub
room
temperatur
minut
pb
ad
final
volum
ml
cell
pellet
centrifug
resuspend
tri
edta
buffer
contain
acidwash
glass
bead
disrupt
min
cell
disruptor
geni
scientif
industri
bohemia
ny
usa
cell
lysat
centrifug
clarifi
supernat
transfer
steril
microtub
spike
target
level
describ
microb
panel
independ
confirm
cdc
laboratori
follow
briefli
spike
sampl
extract
use
magna
pure
compact
instrument
total
nucleic
acid
isol
kit
extern
lysi
protocol
roch
appli
scienc
indianapoli
usa
elut
final
volum
extract
prior
na
extract
differ
specimen
type
process
via
altern
method
sputum
sampl
first
incub
dithiothreitol
solut
thermofish
scientif
waltham
usa
room
temperatur
hour
prior
extract
blood
sampl
blood
first
mix
bacteri
lysi
buffer
roch
ph
neutral
buffer
proteinas
k
mgml
subsequ
incub
ambient
temperatur
minut
glass
bead
mg
mm
ad
cell
disrupt
twice
one
minut
rpm
solut
centrifug
g
one
minut
supernat
use
extract
stool
mg
mix
ml
pb
briefli
centrifug
pellet
particul
four
hundr
supernat
combin
bacteri
lysi
buffer
roch
ph
neutral
buffer
proteinas
k
mgml
incub
ambient
temperatur
minut
glass
bead
mg
ad
cell
disrupt
twice
one
minut
rpm
solut
centrifug
g
one
minut
supernat
use
extract
na
eluat
store
use
pool
specimen
panel
compris
ten
sampl
member
spike
bacteri
pathogen
andor
rnabas
viru
assess
na
extract
effici
three
specimen
matric
tabl
panel
compris
seven
spike
posit
three
unspik
neg
sampl
label
sputum
blood
stool
sputum
spike
mtb
andor
influenza
viru
whole
blood
spike
pneumonia
andor
bacteriophag
stool
spike
typhimurium
andor
phage
input
amount
test
microb
use
spike
semiquantit
determin
via
pcr
cross
threshold
ct
valu
deriv
na
extract
variou
agent
intent
spike
sampl
suffici
na
repres
high
ct
medium
ct
low
ct
amount
test
microb
na
specimen
panel
correspond
level
one
microb
andor
sputum
sp
panel
prepar
pool
ml
raw
human
sputum
blend
creat
homogen
mixtur
homogen
split
ten
ml
aliquot
eight
aliquot
spike
mtb
cell
andor
influenza
virion
correspond
high
medium
low
ct
level
subsequ
mix
creat
uniform
distribut
mtb
cell
influenza
virion
respect
test
panel
sampl
sp
panel
sampl
dispens
ml
aliquot
later
use
whole
blood
bl
split
ten
ml
aliquot
eight
aliquot
spike
vari
concentr
pneumonia
phage
correspond
high
medium
low
ct
level
spike
blood
panel
mix
ensur
even
distribut
spike
agent
ten
bl
panel
aliquot
ml
volum
construct
stool
st
panel
wv
stool
homogen
pb
prepar
blender
aliquot
ten
ml
volum
eight
sampl
spike
typhimurium
andor
stock
correspond
high
medium
low
ct
level
distribut
ml
aliquot
sampl
set
prepar
tube
frozen
use
dri
iceethanol
bath
store
ship
use
ensur
ct
valu
spike
sampl
within
expect
rang
dna
rna
extract
repres
aliquot
panel
follow
construct
na
extract
analyz
real
time
rtpcr
assay
specif
spike
microb
lowspik
sampl
repres
target
microb
also
process
freez
thaw
cycl
ensur
sampl
integr
na
extract
three
specimen
panel
independ
test
rtpcr
cdc
confirm
origin
test
data
deriv
path
laboratori
ct
valu
typic
close
agreement
path
na
extract
trace
amount
mtb
dna
consist
detect
sampl
supposedli
mtb
neg
sampl
sampl
remov
sputum
panel
therefor
final
sp
panel
compris
nine
sampl
present
triplic
aliquot
panel
member
remain
blood
stool
panel
present
triplic
test
aliquot
less
three
replic
across
three
specimen
panel
blind
via
fourdigit
number
ship
overnight
dri
ice
develop
confirm
integr
cold
chain
upon
receipt
develop
ask
document
amount
sampl
use
na
extract
final
elut
volum
time
requir
number
user
step
extract
panel
na
extract
develop
frozen
ship
cdc
laboratori
dri
ice
via
overnight
courier
extract
store
test
ultim
blind
na
extract
test
triplic
via
cdc
real
time
rtpcr
protocol
correspond
microbi
na
three
pcr
reaction
triplic
aliquot
per
panel
member
ct
valu
share
path
laboratori
subsequ
analys
creat
acronym
assur
list
key
attribut
necessari
effect
point
care
test
eg
rapid
diagnost
test
appli
mani
attribut
na
extract
technolog
screen
studi
except
e
equipmentfre
deliver
sinc
technolog
requir
devic
none
technolog
current
manufactur
market
scale
term
afford
develop
consid
technolog
cost
per
test
score
price
ss
sensit
specif
data
point
address
analyt
perform
data
describ
result
section
address
u
userfriendli
r
rapid
appli
number
step
requir
perform
extract
turnaround
time
method
respect
three
polar
plot
one
specimen
panel
gener
develop
base
two
target
na
within
panel
assur
compon
individu
normal
rang
low
high
score
metric
optim
valu
measur
categori
five
normal
paramet
assur
calcul
plot
equal
weight
averag
paramet
calcul
target
microb
averag
pool
reaverag
base
sampl
type
also
three
sampl
type
valu
use
rank
develop
term
assur
real
time
rtpcr
ct
valu
origin
microbespik
challeng
panel
test
path
predominantli
qiagen
kit
use
refer
standard
compar
variou
na
extract
sputum
blood
stool
see
path
column
tabl
cdc
qualifi
three
panel
ensur
specimen
yield
similar
result
path
analys
freez
ship
nucleic
acid
extract
via
differ
platform
roch
magnapur
analysi
realtim
rtpcr
analysi
see
cdc
column
tabl
data
sp
bl
panel
extract
magnapur
cdc
close
correl
qiagen
path
data
varianc
observ
mean
ct
valu
tabl
howev
stool
panel
data
show
greater
varianc
although
ct
valu
similar
cdc
path
result
tabl
less
typhimurium
dna
detect
cdc
na
extract
mid
highspik
st
panel
member
amplif
detect
lowspik
sampl
may
due
path
use
two
separ
qiagen
kit
extract
dna
rna
respect
stool
order
optim
na
recoveri
cdc
laboratori
perform
singl
total
na
extract
method
magnapur
incorpor
brief
centrifug
liquefi
stool
sampl
reduc
debri
prior
extract
centrifug
step
may
explain
differ
seen
typhimurium
dna
level
mani
bacteri
cell
would
like
remov
step
except
typhimurium
cdc
result
verifi
target
na
level
panel
tabl
indic
qiagen
magnapur
method
use
either
laboratori
gave
typic
similar
rtpcr
result
annot
complet
real
time
rtpcr
data
set
group
avail
onlin
http
dataverseharvardedudataversessb
develop
complet
na
extract
use
respect
technolog
ship
extract
cdc
two
minor
deviat
observ
develop
e
ship
two
three
sampl
provid
one
extract
sampl
develop
c
contain
insuffici
elut
volum
allow
influenza
screen
mtb
except
na
extract
deriv
triplic
panel
member
test
triplic
realtim
rtpcr
result
nine
data
point
per
panel
member
mean
ct
valu
calcul
microb
na
panel
sampl
tabl
sensit
specif
calcul
develop
technolog
score
cdc
path
refer
dataset
along
confid
interv
summar
tabl
na
extract
retest
initi
screen
confirm
whether
procedur
error
account
unexpect
result
root
caus
analysi
enabl
identif
mislabel
sampl
two
develop
final
rtpcr
data
correct
base
repeat
test
account
origin
label
error
complet
annot
data
set
develop
publicli
avail
http
dataverseharvardedudataversessb
develop
c
extract
influenza
rna
spike
sampl
sensit
develop
e
extract
influenza
rna
rtpcr
test
posit
use
low
sampl
extract
eg
three
fals
posit
replic
report
one
extract
indic
potenti
cross
contamin
analys
influenza
rna
produc
develop
e
extract
technolog
show
overal
sensit
influenza
rna
influenza
rna
medium
high
spike
sampl
produc
detect
level
two
develop
f
lowlevel
sampl
score
neg
technolog
develop
b
produc
influenza
rna
sp
extract
even
highspik
level
specif
consid
develop
score
except
develop
e
score
overal
develop
c
highest
concord
predic
method
influenza
rna
extract
sputum
name
qiagen
manual
extract
path
magnapur
cdc
better
overal
extract
perform
observ
mtb
tabl
develop
correctli
extract
mtb
dna
spike
sampl
wherea
develop
c
e
manag
produc
mtb
dna
mtb
spike
sampl
though
consist
three
replic
mtb
lowlevel
spike
sampl
develop
b
abl
extract
detect
mtb
dna
sampl
highestspik
level
note
mtb
dna
extract
develop
ct
valu
gener
test
gener
lower
magnapur
cdc
manual
path
data
set
tabl
indic
mtb
develop
extract
method
effici
path
cdc
refer
method
analys
extract
develop
achiev
sensit
wherea
extract
develop
b
e
f
demonstr
significantli
lower
sensit
extract
technolog
score
well
regard
specif
develop
b
c
e
f
achiev
howev
develop
score
least
well
six
group
extract
gener
specif
possibl
due
cross
contamin
affect
mtbneg
sampl
tabl
overal
mtb
dna
extract
sputum
develop
concord
refer
method
amongst
six
technolog
develop
c
also
score
well
sputum
panel
overal
develop
c
demonstr
highest
concord
refer
method
consid
simultan
extract
dna
rna
target
extract
develop
b
e
f
contain
detect
amount
rna
across
spike
rang
high
low
tabl
howev
extract
develop
agreement
replic
compar
magnapur
cdc
qiagen
path
refer
data
develop
extract
gave
consist
lower
ct
valu
refer
data
indic
effect
purif
overal
extract
develop
f
correctli
correspond
posit
sampl
extract
neg
sampl
gave
fals
posit
rtpcr
result
presum
cross
contamin
event
develop
e
detect
lowspik
sampl
replic
correctli
detect
replic
higherspik
panel
member
rtpcr
extract
develop
b
correctli
identifi
major
replic
spike
surprisingli
mani
unspik
sampl
extract
also
score
rtpcr
posit
tabl
result
poor
specif
panel
upon
investig
discov
develop
b
routin
use
develop
work
laboratori
possibl
reagent
contamin
phage
amplicon
sampl
develop
c
nonreact
respect
sampl
result
poor
sensit
observ
specif
develop
c
e
develop
f
close
follow
overal
develop
rank
highest
challeng
whole
blood
sensit
specif
develop
f
follow
observ
sensit
specif
respect
develop
e
slightli
lower
sensit
specif
magnapur
extract
gave
lowest
ct
valu
across
panel
rang
pneumonia
dna
extract
whole
blood
mani
develop
technolog
demonstr
good
perform
spike
rang
correctli
gener
rtpcr
posit
result
tabl
howev
extract
develop
consist
rtpcr
posit
spike
replic
result
sensit
replic
extract
lowspik
sampl
andor
prepar
develop
c
e
f
gener
variabl
rtpcr
result
develop
e
f
show
higher
sensit
respect
technolog
achiev
specif
develop
b
c
e
score
factor
rna
pneumonia
dna
extract
whole
blood
develop
score
best
overal
similar
ct
valu
refer
assay
use
cdc
path
rna
extract
stool
panel
test
panel
develop
achiev
sensit
replic
extract
deriv
lowspik
sampl
gave
posit
rtpcr
result
tabl
magnapur
assay
also
perform
poorli
compar
qiagen
method
employ
path
extract
develop
f
score
highest
sensit
respect
term
specif
develop
b
extract
appear
confound
potenti
contamin
lesser
degre
observ
blood
panel
extract
develop
demonstr
specif
overal
develop
greatest
concord
extract
rna
compar
six
technolog
develop
f
close
second
posit
sampl
ct
higher
correspond
path
data
indic
extract
andor
copurif
confound
signific
neg
effect
gener
test
result
typhimurium
develop
technolog
whose
na
extract
detect
sensit
interestingli
sensit
score
extract
develop
rel
low
compar
microb
panel
develop
next
best
technolog
score
specif
stool
panel
develop
signific
concord
data
deriv
differ
extract
method
use
path
cdc
compar
competitor
term
rna
dna
extract
follow
develop
f
naat
multipl
factor
may
contribut
diagnost
accuraci
observ
six
technolog
includ
amount
sampl
process
na
extract
final
elut
volum
percentag
eluat
use
amplificationdetect
step
theoret
process
larg
amount
specimen
andor
elut
captur
na
smaller
volum
result
concentr
sampl
thu
increas
likelihood
amplif
target
na
specimen
input
elut
volum
na
extract
method
vari
substanti
among
develop
tabl
input
rang
sputum
process
blood
stool
elut
volum
rang
consist
across
specimen
type
within
technolog
percentag
eluat
among
six
technolog
use
rtpcr
step
vari
less
rang
examin
relationship
sampl
volum
elut
volum
respect
volum
eluat
use
rtpcr
back
calcul
amount
sampl
per
rtpcr
reaction
compar
overal
perform
rank
develop
use
pool
sensit
specif
data
panel
tabl
develop
overal
top
perform
term
na
extract
method
assess
typic
use
largest
amount
input
materi
avail
materi
na
elut
final
volum
result
high
percentag
sampl
use
develop
f
greater
rel
amount
sampl
input
mtb
panel
develop
b
f
also
use
larger
sputum
input
na
elut
volum
achiev
level
sensit
seen
develop
develop
e
rank
third
matric
term
sensit
use
smaller
amount
input
sampl
avail
materi
elut
smallest
volum
record
thu
extract
process
effici
term
extract
methodolog
develop
c
use
small
sampl
input
also
poorer
perform
base
sensit
except
sputum
develop
c
score
best
overal
use
sputum
sampl
develop
b
use
small
sampl
input
blood
stool
respect
elut
largest
eluat
note
amongst
six
group
combin
may
contribut
typic
lower
sensit
observ
across
panel
tabl
goal
studi
identifi
na
extract
technolog
fit
requir
integr
test
devic
molecular
detect
infecti
agent
alreadi
describ
analyt
perform
term
sensit
specif
rtpcr
base
detect
na
extract
compar
refer
method
use
magnapur
cdc
qiagen
kit
path
tabl
import
analyt
perform
metric
consid
rank
technolog
also
appli
assur
criteria
defin
result
section
seri
radar
plot
visual
compar
technolog
sampl
type
assess
target
microb
fig
normal
paramet
panel
averag
panel
also
overal
permit
rank
technolog
comparison
simpli
perform
tabl
data
file
http
dataverseharvardedudataversessb
assur
rank
tabl
compar
perform
rank
display
tabl
develop
f
replac
overal
highest
rank
group
chang
one
two
place
develop
sputum
panel
develop
c
retain
highest
rank
develop
f
second
develop
e
drop
one
place
origin
rank
respect
b
remain
blood
panel
assur
rank
chang
develop
compar
perform
rank
develop
f
c
score
top
rank
respect
rank
develop
e
drop
two
place
third
fifth
whilst
develop
b
score
fourth
drop
sixth
rank
stool
averag
develop
f
rank
highest
develop
b
rank
second
result
repres
signific
increas
two
rank
place
panel
develop
drop
rank
third
sixth
respect
ream
develop
retain
rank
addit
data
inform
suitabl
technolog
incorpor
low
cost
naat
result
slight
chang
overal
rank
technolog
compar
perform
though
rank
algorithm
identifi
develop
f
top
two
technolog
develop
akonni
biosystem
molbio
diagnost
respect
inclus
turnaround
time
tat
manual
step
assur
dataset
underli
reason
molbio
f
move
ahead
akonni
biosystem
molbio
also
good
perform
also
rapid
tat
minut
versu
minut
fewer
user
step
akonni
methodolog
award
higher
rank
via
radar
plot
analys
fig
develop
use
system
autom
differ
degre
molbio
platform
host
cassett
process
sampl
prepar
step
data
develop
b
also
improv
primarili
due
incorpor
fastest
tat
augment
rel
poor
perform
data
tabl
fig
light
find
technolog
offer
akonni
molbio
best
score
consider
enter
next
stage
assess
integr
fulli
autom
standalon
naat
platform
studi
report
initi
screen
six
candid
na
extract
technolog
assess
suitabl
integr
low
cost
naat
cartridg
perform
comparison
two
establish
na
extract
system
offer
roch
magnapur
autom
qiagen
manual
use
contriv
panel
sampl
mimic
common
clinic
specimen
technolog
variou
phase
product
develop
rang
alpha
prototyp
product
close
market
eg
akonni
molbio
therefor
poorer
perform
may
simpli
reflect
devic
method
still
refin
sever
develop
also
note
normal
use
differ
protocol
materi
extract
rna
dna
thu
make
modif
coextract
dna
rna
meet
requir
potenti
integr
naat
consequ
technolog
may
suboptim
condit
impos
studi
investig
diagnost
perform
workflow
technolog
challeng
three
panel
contriv
sampl
repres
common
specimen
type
use
naatbas
diagnosi
multipl
pathogen
sputum
tuberculosi
stool
diarrheal
diseas
eg
shigella
spp
blood
eg
hiv
malaria
typhoid
target
microb
spike
differ
concentr
assess
effect
differ
na
extract
method
across
rang
target
burden
within
complex
matrix
panel
two
spike
microb
select
evalu
effici
extract
dna
rnabas
genom
target
refer
method
typic
gave
best
result
akonni
platform
better
perform
certain
target
pathogen
akonni
heavili
invest
mtb
diagnost
naat
best
class
perform
mtb
like
reflect
expertis
area
specimen
type
associ
microb
chosen
present
differ
challeng
na
extract
term
composit
specimen
matrix
matrix
associ
rtpcr
confound
load
structur
complex
target
microb
eg
acid
fast
gram
positiveneg
bacteria
rnabas
virus
minim
bia
optim
extract
perform
develop
provid
ident
blind
sampl
panel
process
facil
use
equip
oper
train
staff
na
extract
group
subsequ
screen
nation
refer
laboratori
valid
rtpcr
assay
use
platform
reagent
user
protocol
six
technolog
rank
exercis
emphasi
extract
detect
efficaci
target
na
complex
specimen
matric
two
method
use
score
develop
rel
one
base
sole
perform
ie
sensit
specif
includ
turnaround
time
number
manual
step
estim
cost
per
extract
base
perform
akonni
develop
rank
highest
five
six
target
use
three
specimen
panel
akonni
platform
partial
autom
util
trutip
technolog
silica
coat
frit
hous
ml
micropipettor
tip
neg
posit
air
pressur
use
manipul
liquid
lyse
materi
buffer
across
frit
sequenti
captur
wash
elut
na
sampl
use
autom
pipettor
molbio
develop
e
rank
second
third
respect
consist
detect
na
replic
lowest
spike
sampl
molbio
platform
trueprep
auto
batteri
power
instrument
host
cartridgebas
extract
system
util
boom
chemistri
captur
purifi
na
observ
specif
method
rel
uniform
among
five
six
technolog
one
develop
c
score
laboratori
procedur
possibl
contamin
specimen
extract
occur
prepar
process
handl
test
observ
extract
develop
b
risk
operatorintroduc
contamin
lower
autom
system
use
observ
akonni
molbio
platform
vari
degre
autom
good
laboratori
practic
molecular
test
laboratori
follow
laboratori
minim
potenti
contamin
specimen
extract
pcr
reaction
order
ensur
integr
result
incorpor
addit
metric
relat
user
input
tat
eas
use
assess
develop
result
slight
chang
rank
molbio
rank
highest
akonni
second
develop
rank
lower
perform
score
significantli
better
factor
includ
part
due
equal
weight
five
metric
use
develop
claim
focu
perform
extend
process
time
compar
rapid
process
time
limit
number
user
step
feasibl
protocol
refin
autom
challeng
address
ideal
test
oper
must
minim
user
input
cost
bias
develop
report
us
per
extract
feasibl
yet
none
either
product
manufactur
scale
confirm
accur
meet
price
sever
limit
method
use
headtohead
studi
firstli
stool
blood
use
gener
contriv
sampl
acquir
singl
individu
may
repres
often
challeng
heterogen
seen
sampl
differ
patient
composit
sputum
typic
stool
healthi
donor
repres
matric
cours
activ
infect
eg
presenc
blood
although
rna
dnabas
microb
use
spike
provid
standard
mean
assess
differ
extract
effici
variou
technolog
target
chemic
inactiv
tuberculosi
cell
may
repres
challeng
cell
lysi
live
mycobacteria
similarli
pneumonia
prone
autolysi
cultur
late
growth
phase
cell
prepar
spike
may
partial
compromis
cultur
harvest
storag
studi
focus
na
extract
effici
term
detect
specif
target
na
address
matrix
effect
associ
potenti
inhibitori
compound
could
affect
perform
rtpcr
reaction
feasibl
low
rank
method
highli
effici
extract
na
associ
copurif
confound
mask
former
inhibit
amplif
rtpcr
variat
ct
valu
use
semiquantit
assess
na
extract
effici
wide
rang
sampl
input
elut
volum
use
differ
method
make
difficult
directli
compar
normal
extract
effici
intent
studi
assess
differ
na
extract
tool
identifi
best
class
candid
potenti
integr
afford
autom
test
cartridg
offer
high
diagnost
accuraci
combin
suitabl
amplif
assay
akonni
biosystem
molbio
rank
best
via
either
score
method
compani
na
extract
product
market
exercis
highlight
basic
fact
product
valid
releas
onto
market
typic
better
perform
prototyp
still
develop
sever
key
element
necessari
meet
goal
beyond
scope
studi
includ
design
manufactur
multipl
featur
integr
singl
test
cartridg
increas
design
complex
typic
rais
manufactur
cost
andor
failur
mode
one
area
futur
investig
optim
maximum
volum
eluat
amplif
detect
eluat
aliquot
thereof
liquid
necessari
add
lyophil
amplif
reagent
parallel
evalu
suitabl
candid
na
amplif
recent
complet
present
companion
manuscript
ultim
intend
assess
suitabl
method
na
extract
amplificationdetect
integr
potenti
enabl
develop
lowcost
point
care
naat
meet
clinic
econom
challeng
use
rl
